CYTK
CYTK clinical trials: CYTOKINETICS INC
Every trial on ClinicalTrials.gov where CYTOKINETICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 46
- Trials linked
- 41
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CYTK on the catalyst calendar · CYTK registry changes
- Primary completion Sep 2027Sponsor estimatePhase 3NCT06736574Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionCytokinetics · Heart FailureRecruitingCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 2/Phase 3NCT04848506Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMCytokinetics · Symptomatic Hypertrophic Cardiomyopathy (HCM)Enrolling by invitationCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2026ActualPhase 3NCT06081894A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic...Cytokinetics · Symptomatic Non-Obstructive Hypertrophic CardiomyopathyActive, not recruitingCYTKLeadSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2NCT06793371AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFCytokinetics · Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)RecruitingCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2030Sponsor estimatePhase 2/Phase 3NCT06412666A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).Cytokinetics · PediatricActive, not recruitingCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2025ActualPhase 3NCT05767346Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMCytokinetics · Obstructive Hypertrophic Cardiomyopathy (oHCM)CompletedCYTKLeadSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2023ActualPhase 3NCT05186818Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMCytokinetics · Obstructive Hypertrophic Cardiomyopathy (oHCM)CompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2023ActualPhase 2NCT04219826Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With...Cytokinetics · Hypertrophic Cardiomyopathy (HCM)CompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2024ActualPhase 1NCT05877053A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult ParticipantsCytokinetics · Healthy ParticipantsCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2020ActualPhase 1NCT04175808Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy AdultsCytokinetics · QT Intervals ChangesCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 3, 2020ActualPhase 1NCT03767855A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsCytokinetics · Symptomatic Obstructive Hypertrophic CardiomyopathyCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2023ActualPhase 3NCT04944784A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)Cytokinetics · Amyotrophic Lateral SclerosisTerminatedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2023ActualPhase 1NCT05662215A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult ParticipantsCytokinetics · Healthy ParticipantsTerminatedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 7, 2023ActualPhase 3NCT05442775A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)Cytokinetics · Amyotrophic Lateral SclerosisTerminatedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2023ActualPhase 1NCT05924815Study to Evaluate the Effect of Aficamten Administration on QT/QTc IntervalCytokinetics · Healthy ParticipantsCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 8, 2021ActualPhase 3NCT03759392Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureCytokinetics · Heart Failure With Reduced Ejection FractionCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 14, 2020ActualPhase 3NCT02929329Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionCytokinetics · Heart FailureCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2026Sponsor estimatePhase 3NCT04464525Omecamtiv Mecarbil Post-trial Access StudyCytokinetics · Chronic Heart Failure With Reduced Ejection FractionWithdrawnCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2017ActualPhase 2NCT02695420Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionCytokinetics · Heart Failure With Reduced Ejection FractionCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2016ActualPhase 1NCT02601001Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese AdultsCytokinetics · Healthy VolunteerCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 22, 2015ActualPhase 2NCT01786512COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart FailureCytokinetics · Modified Release Oral FormulationCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2013ActualPhase 1NCT01737866Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal InsufficiencyCytokinetics · Heart FailureCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2013ActualPhase 2NCT01300013Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic...Cytokinetics · Heart FailureCompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2011ActualPhase 2NCT01077167Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure PatientsCytokinetics · Heart FailureWithdrawnCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 26, 2018ActualPhase 3NCT02936635A Study for Patients Who Completed VITALITY-ALS (CY 4031)Cytokinetics · Amyotrophic Lateral Sclerosis (ALS)CompletedCYTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 21 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner